Number and Volume of Demyelinative Plaques Can Predict the Response to Treatment in Patients with Multiple Sclerosis

Document Type : Original Article (s)

Authors

1 Associate Professor, Department of Radiology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

2 Professor, Department of Neurology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

3 Resident, Department of Radiology, School of Medicine And Student Research Committee, Isfahan University of Medical Sciences, Isfahan, Iran

4 Student of Medicine, London University, London, England

5 Radiologist, Isfahan, Iran

6 Resident, Department of Pediatrics, School of Medicine And Student Research Committee, Isfahan University of Medical Sciences, Isfahan, Iran

Abstract

Background: Interferon β (IFN- β) has been proved as an effective treatment for relapsing-remitting type of multiple sclerosis (MS), however not all patients respond to this treatment. The aims of the present study were to assess the changes in number and volume of demyelinating plaques on magnetic resonance imaging (MRI) as surrogate markers for response to IFN-β treatment in patients with relapsing-remitting MS after one year of follow-up.Methods: 41 patients with relapsing-remitting MS were recruited and IFN β-1-a treatment was started for them. Brain MRI were obtained at baseline and after one year of treatment. the number of plaques (NP) and volume of plaques (VP) were determined. The criterion for response to treatment on MRI was defined as 50% decrease in mean NP or VP.Findings: There was a significant decrease in the NP and VP after treatment (P < 0.001). The cut-off point defined for analyzing the data was 50% decrease in mean NP or VP.The specificity of NP and VP as two criteria was the same and equals to 100%. The sensitivity of the NP was 65.5% and that for VP was 90.6%. Furthermore, if the cut-off point for the NP is set at 10%, the sensitivity of NP as a criterion will be the same as that of VP (90.6%). Conclusion: These data suggest that both the NP and VP could be two reliable imaging criteria for the assessment of response to treatment on MRI. However, the VP was more accurate than the NP.

Keywords

References

  1. Kappos L, Traboulsee A, Constantinescu C, Eralinna JP, Forrestal F, Jongen P, et al. Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS. Neurology 2006; 67(6): 944-53.
  2. Grigoriadis N. Interferon beta treatment in relapsing-remitting multiple sclerosis. A review. Clin Neurol Neurosurg 2002; 104(3): 251-8.
  3. Rio J, Comabella M, Montalban X. Predicting responders to therapies for multiple sclerosis. Nat Rev Neurol 2009; 5(10): 553-60.
  4. Barkhof F, Filippi M, Miller DH, Scheltens P, Campi A, Polman CH, et al. Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain 1997; 120 (Pt 11): 2059-69.
  5. Tintore M, Rovira A, Martinez MJ, Rio J, Diaz-Villoslada P, Brieva L, et al. Isolated demyelinating syndromes: comparison of different MR imaging criteria to predict conversion to clinically definite multiple sclerosis. AJNR Am J Neuroradiol 2000; 21(4): 702-6.
  6. Paty DW, Li DK. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group. Neurology 1993; 43(4): 662-7.
  7. Simon JH, Jacobs LD, Campion M, Wende K, Simonian N, Cookfair DL, et al. Magnetic resonance studies of intramuscular interferon beta-1a for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group. Ann Neurol 1998; 43(1): 79-87.
  8. Li DK, Paty DW. Magnetic resonance imaging results of the PRISMS trial: a randomized, double-blind, placebo-controlled study of interferon-beta1a in relapsing-remitting multiple sclerosis. Prevention of Relapses and Disability by Interferon-beta1a Subcutaneously in Multiple Sclerosis. Ann Neurol 1999; 46(2): 197-206.
  9. Rudick RA, Lee JC, Simon J, Ransohoff RM, Fisher E. Defining interferon beta response status in multiple sclerosis patients. Ann Neurol 2004; 56(4): 548-55.
  10. Sormani MP, Bonzano L, Roccatagliata L, Cutter GR, Mancardi GL, Bruzzi P. Magnetic resonance imaging as a potential surrogate for relapses in multiple sclerosis: a meta-analytic approach. Ann Neurol 2009; 65(3): 268-75.
  11. Rio J, Rovira A, Tintore M, Huerga E, Nos C, Tellez N, et al. Relationship between MRI lesion activity and response to IFN-beta in relapsing-remitting multiple sclerosis patients. Mult Scler 2008; 14(4): 479-84.
  12. Tomassini V, Paolillo A, Russo P, Giugni E, Prosperini L, Gasperini C, et al. Predictors of long-term clinical response to interferon beta therapy in relapsing multiple sclerosis. J Neurol 2006; 253(3): 287-93.
  13. Pozzilli C, Prosperini L, Sbardella E, De GL, Onesti E, Tomassini V. Post-marketing survey on clinical response to interferon beta in relapsing multiple sclerosis: the Roman experience. Neurol Sci 2005; 26(Suppl 4): S174-S178.
  14. Saadatnia M, Etemadifar M, Maghzi AM. Multiple sclerosis in Isfahan, Iran. International Review of Neurobiology 2007; 79: 357-75.
  15. Rio J, Nos C, Tintore M, Tellez N, Galan I, Pelayo R, et al. Defining the response to interferon-beta in relapsing-remitting multiple sclerosis patients. Ann Neurol 2006; 59(2): 344-52.
  16. Gauthier SA, Glanz BI, Mandel M, Tsagkaropoulos A, Neema M, Stankiewicz J, et al. Incidence and factors associated with treatment failure in the CLIMB multiple sclerosis cohort study. J Neurol Sci 2009; 284(1-2): 116-9.
  17. Prosperini L, Gallo V, Petsas N, Borriello G, Pozzilli C. One-year MRI scan predicts clinical response to interferon beta in multiple sclerosis. Eur J Neurol 2009; 16(11): 1202-9.
Journal of Isfahan Medical School
Volume 29, Issue 154 - Serial Number 154
July and August 2011
Pages 1341-1346

Files

History

  • Receive Date: 27 August 2011
  • Revise Date: 27 May 2024
  • Accept Date: 06 April 2022

Share

How to cite

Statistics